AnalyzeDirect

Sharma R, Buitrago S, Pitoniak R, Gibbs JF, Curtin L, Seshadri M, Repasky EA, Hylander BL. Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy. Pancreas. March 2014;43(2):298-305.

Full Text – Open Access

Publication Date
March 2014

How Analyze was Used
“Following image acquisition, raw image sets were transferred to a processing workstation and processed using the medical imaging software, Analyze (AnalyzeDirect, version 7.0; Overland Park, KS). Primary tumor volumes and metastatic burden (mm³) were calculated from manually traced regions-of-interest (ROI).”

Keywords
Apo2L/TRAIL
Implantation Site
Metastatic Model
Patient Pancreatic Tumor Xenograft

Author Affiliation(s)
Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, US. (RS, JFG)

Laboratory Animal Resources, Roswell Park Cancer Institute, Buffalo, NY, US. (SB, LC)

Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, US. (RP, EAR, BLH)

Department of Pharmacology, Roswell Park Cancer Institute, Buffalo, NY, US. (MS)

ID# 30

Tags: Apo2L/TRAIL, Implantation Site, Metastatic Model, Patient Pancreatic Tumor Xenograft